5 articles in this category
Negative free cash flow offsets strong gross margin and forward P/E; no news catalyst but technical volatility suggests short-term upside.
Despite negative gross margins and heavy cash burn, recent Q2 revenue growth and strategic updates signal improving commercial traction, suggesting near-term upside.
Improving losses and strong revenue growth meet NHS trial momentum, fueling near-term upside potential.
Strong cash flow growth and 10% revenue expansion meet rising institutional interest, signaling near-term upside momentum.
Strong gross margin and improving cash flow meet positive FDA news catalyst — stock poised for near-term rebound.